Boston Scientific and The Medicines Company will co-promote Promus Premier in USA


Boston Scientific and The Medicines Company have announced a co-promotion agreement for the now FDA-approved Promus Premier stent system. Therefore, The Medicines Company’s acute cardiovascular care sales force will collaborate with the Boston Scientific Interventional Cardiology sales force to provide promotional support for the stent system in USA hospitals beginning January 2014.

“The Medicines Company’s established and highly complementary product portfolio in interventional cardiology will enhance the capabilities of our sales force as we introduce the Promus Premier system in the US market,” says Matt Franklin, vice president, Interventional Cardiology Global Marketing, Boston Scientific. “This collaborative agreement brings together two of the market leading providers of interventional cardiology and acute care solutions to better support our customers and the patients they serve.”